Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial

To determine the safety and efficacy of nebivolol in elderly heart failure (HF) patients with renal dysfunction.

[1]  A. Rigby,et al.  Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. , 2010, International journal of cardiology.

[2]  A. Cohen-Solal,et al.  Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.

[3]  B. Fagerberg,et al.  The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). , 2009, Journal of cardiac failure.

[4]  P. Ponikowski,et al.  Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. , 2008, European heart journal.

[5]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[6]  H. Hillege,et al.  Anemia and mortality in heart failure patients a systematic review and meta-analysis. , 2008, Journal of the American College of Cardiology.

[7]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[8]  K. Alexander,et al.  Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. , 2008, Journal of the American College of Cardiology.

[9]  P. Borne,et al.  The Effect of Nebivolol and Atenolol on Renal and Systemic Haemodynamics in Hypertensive Patients , 2007 .

[10]  D. J. Veldhuisen,et al.  Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction , 2007, European journal of heart failure.

[11]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[12]  D. Whellan,et al.  Renal dysfunction in heart failure patients: what is the evidence? , 2007, Heart Failure Reviews.

[13]  A. Borg,et al.  β blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure , 2006, Heart.

[14]  G. Navis,et al.  Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.

[15]  M. Rich,et al.  Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial. , 2006, Archives of internal medicine.

[16]  W. Frishman,et al.  Nebivolol: New Therapy Update , 2006, Cardiology in review.

[17]  M. Nangaku,et al.  Pathogenesis of renal anemia. , 2006, Seminars in nephrology.

[18]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[19]  T. McDonagh,et al.  The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure , 2006, European journal of heart failure.

[20]  K. Swedberg,et al.  Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. , 2005, European heart journal.

[21]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[22]  M. Rich.  Office management of heart failure in the elderly. , 2005, The American journal of medicine.

[23]  G. Bakris,et al.  β-Blocker use in long-term dialysis patients: Association with hospitalized heart failure and mortality , 2005 .

[24]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[25]  M. Dorobanțu,et al.  The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. , 2005, European journal of pharmacology.

[26]  G. Bakris,et al.  beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. , 2004, Archives of internal medicine.

[27]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[28]  Aditya K. Gupta.  New Therapy Update , 2003 .

[29]  L. Ignarro,et al.  Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. , 2002, Nitric oxide.

[30]  C. Jurkovitz,et al.  Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. , 2002, Journal of the American Society of Nephrology : JASN.

[31]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[32]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[33]  W. Hermann,et al.  Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .

[34]  M. Mcclellan,et al.  Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. , 2001, The American journal of medicine.

[35]  P. Russo,et al.  Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. , 2001, Journal of the American College of Cardiology.

[36]  H. Wiemann,et al.  Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. , 2001, European journal of heart failure.

[37]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[38]  G. Dibona,et al.  Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. , 1999, Circulation.